Clin Gastroenterol Hepatol. 2018 Mar 2. pii: S1542-3565(18)30225-8. doi: 10.1016/j.cgh.2018.02.037. [Epub ahead of print]
Effects of Treatment of Chronic HBV Infection on Patient-reported Outcomes.
Younossi ZM1, Stepanova M2, Janssen HLA3, Agarwal K4, Nguyen MH5, Gane E6, Tsai N7, Younossi I2, Racila A2.
Author information
1
Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA. Electronic address: [email protected].
2
Center for Outcomes Research in Liver Disease, Washington DC, USA.
3
Toronto Centre for Liver Disease, University Health Network, Canada.
4
Institute of Liver Studies, Kings College Hospital, London, United Kingdom.
5
Stanford University Medical Center, Palo Alto, California, USA.
6
Auckland Clinical Studies, Auckland, New Zealand.
7
Queens Medical Center, University of Hawaii, USA.
Abstract
BACKGROUND AND AIM:
Chronic infection with hepatitis B virus (HBV) causes liver disease and cirrhosis. It is not clear how treatment of chronic HBV infection affects patient-reported outcomes (PROs). We aimed to assess changes in PROs in patients treated for chronic HBV infection.
METHODS:
We collected and analyzed PRO data from 242 patients with chronic HBV infection (without advanced fibrosis or cirrhosis) enrolled in 2 international phase 2 blinded controlled clinical trials from 2015 through 2017. In these trials, patients were treated with an approved oral antiviral regimen (tenofovir, entecavir, adefovir, lamivudine, or telbivudine) and then randomly assigned to groups given vesatolimod (an oral agonist of toll like receptor 7) or placebo. PROs were collected using the Short Form-36, the Chronic Liver Disease Questionnaire, and the Work Productivity and Activity Impairment: Specific Health Problem scoring system before treatment, on treatment weeks 12, 24, and 48.
RESULTS:
We did not observe significant differences in PROs between patients receiving vesatolimod vs placebo. At baseline, patients with viral suppression (level of HBV DNA <20 IU/mL) had higher PRO scores (by up to +10.6% of a PRO range size). During treatment, there were significant increases in scores for some domains of Chronic Liver Disease Questionnaire and in General Health scores of Short Form-36 (increases of up to 4.9%; P<.05). Patients with a decrease of at least 2.7 log10 IU/mL in level of HBV DNA had substantially larger increases in PRO scores (mean increases of up to 7.2% by week 48; P<.05 for 10 of 22 studied PROs). In multivariate analysis, a reduction in viral load was independently associated with increases in PROs (betas values up to 1.6% per log10 IU/mL decrease; P<.05).
CONCLUSIONS:
In an analysis of data from phase 2 trials, we associated active treatment of chronic HBV infection with increased PRO scores. These findings support inclusion of PRO endpoints in assessments of efficacy and safety in clinical trials of treatments for HBV infection.
我们没有观察到接受vesatolimod与安慰剂的患者之间PRO的显着差异。在基线时，病毒抑制的患者（HBV DNA水平<20 IU / mL）具有更高的PRO评分（高达PRO范围大小的+ 10.6％）。在治疗期间，慢性肝病调查问卷的一些领域和Short Form-36的一般健康评分（增加至4.9％; P <0.05）的评分显着增加。 HBV DNA水平下降至少2.7 log10 IU / mL的患者PRO评分有显着增加（第48周平均增加至7.2％; 22位研究PRO中10位P <0.05）。在多变量分析中，病毒载量的减少与PROs增加独立相关（每log10 IU / mL下降，β值高达1.6％; P <0.05）。
结论：